IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients by Wang, Weili et al.
IDO Immune Status after Chemoradiation May Predict Survival in 
Lung Cancer Patients
Weili Wang1,*, Lei Huang2,*, Jian-Yue Jin1,#, Shruti Jolly3, Yong Zang4, Huanmei Wu5, Li 
Yan1, Wenhu Pi1, Lang Li4, Andrew L. Mellor2, and Feng-Ming (Spring) Kong1,#
1Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN 
46202
2Institute of Cellular Medicine, Faculty of Medical Sciences, Framlington Place, Newcastle 
University, Newcastle-upon-Tyne NE2 4HH, UK
3Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109
4Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN 46202
5Indiana University School of Informatics and Computing, Indianapolis, IN 46202
Abstract
Host immunity influences the impact of radiotherapy (RT) in cancer but mechanistic connections 
remain obscure. In this study, we investigated the relationship of indoleamine 2,3-dioxygenase 
(IDO) systemic activity on clinical outcomes in RT-treated non-small cell lung cancer (NSCLC). 
IDO-mediated production of kynurenine and the kynurenine:tryptophan ratio in patient blood 
serum were determined for stage III NSCLC patients at times before, during and after RT 
administration and then correlated to overall survival (OS), progression-free survival and disease 
progression rate in patients. We found the impact of RT on these serum IDO markers to be 
heterogeneous in patients. On average, kynurenine:tryptophan ratios were reduced during RT but 
restored after RT. Notably, both baseline levels of kynurenine:tryptophan and changes in the levels 
of kynurenine after RT were significantly associated with OS. When combined, favorable change 
and favorable baseline corresponded with very long-term OS (median OS was not reached after 57 
months median follow-up). Favorable change combined with unfavorable baseline still 
corresponded with a lack of distant metastases. Our results suggest that RT alters IDO-mediated 
immune status in NSCLC patients and that changes in this serum biomarker may be useful to 
predict outcomes and perhaps personalize RT dosage to improve survival.
Introduction
Non-small cell lung cancer (NSCLC) accounts for 80-85% of lung cancer, which is the 
leading cause of cancer death in the United States (1). Approximately 64% of patients with 
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NSCLC require radiotherapy (RT) at least once during their course of disease (2). Recently, 
it has been reported that radiation induced tumor killing can activate the immune system by 
generating tumor specific antigens and converting the tumor into an individualized in situ 
vaccine (3). Animal studies have demonstrated that a combination of hypo-fractionated RT 
with immunotherapy generated synergetic effects on local tumor control and even abscopal 
effects for tumor killing outside the treatment fields (3-5). The RT abscopal effect has been 
reported in a few clinical cases, including one melanoma case in the New England Journal of 
Medicine (4).
Indoleamine 2, 3-dioxygenase (IDO) is an intercellular enzyme that converts the essential 
amino acid tryptophan into kynurenine through the IDO/kynurenine pathway (6). IDO 
depletes tryptophan in the tumor microenvironment and activates immune checkpoint via 
amino acid sensor general control nonderepressible 2 (GCN2) (7,8). Kynurenine, the direct 
metabolite of this pathway, and its further downstream metabolites, promotes potent immune 
suppression by enhancing Foxp3-regulatory T cell functions and attenuating responses of 
effector T cells and natural killer cells (9,10). Previous studies have validated IDO as a 
potent immune checkpoint in cancers and other chronic inflammatory diseases (11-13). 
Because tryptophan and kynurenine concentrations can be measured from patients' serum, 
IDO activity can be monitored by computing kynurenine to tryptophan (K:T) ratio. Clinical 
studies have reported that IDO activity correlated with the number of tumor infiltrating 
lymphocytes in esophageal and colorectal cancers (14,15), and elevated IDO activity 
correlated with poor clinical outcomes in several types of cancers (16-19), including lung 
cancer (20-22). These clinical data further support that IDO is an immune checkpoint that 
mediates anti-tumor immune activity. However, it is not clear how this IDO-mediated 
immune activity changes during or after RT in cancer patients, and whether these changes 
have any impact on tumor control or survival.
In this study, we hypothesized that RT can alter the IDO-mediated anti-tumor immune 
activity which will impact on tumor progression or survival in patients with NSCLC. To test 
this hypothesis, we assessed IDO-mediated immune activity by quantifying the key 
molecules associated with the IDO checkpoint, including kynurenine and the K:T ratio (a 
commonly used surrogate for IDO activity), at pre-RT, 2-week (during-RT), 4-week (during-
RT) and post-RT (3 months after RT completion). We then performed survival analysis to 
correlate these parameters and their changes with progression free survival (PFS), overall 
survival (OS) and distant tumor progression.
Materials and Methods
Patients and Treatment
Patients with stage III inoperable/unresectable NSCLC enrolled institutional review board 
(IRB) approved prospective protocols were eligible. The protocols were conducted 
according to requirements of Belmont Report and U.S. Common Rules. All subjects signed 
informed written consent before enrollment. All patients received conventionally 
fractionated daily RT, which was given using 3D conformal radiotherapy (3DCRT) as 
previously described (23,24). Details of these prospective trials were summarized in 
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supplement Table S1. Equivalent dose at 2 Gy fraction (EQD2) were computed for those 
received other than 2 Gy daily doses, using alpha/beta of 10.
Patients Follow-up and Samples/Clinical Data Collection
Patients were examined weekly during the course of RT, followed up approximately every 3 
months during the first year, every 6 months during the second year and then annually 
thereafter. Clinical and follow-up data, including age, gender, smoking history, histology, 
clinical stage, tumor volume, Karnofsky performance score (KPS), EQD2 and 
chemotherapy, were recorded prospectively up to 2 years after completion of RT. Red top 
blood collection tubes without anticoagulants were used for serum. Blood samples of 
patients were collected at up to four time points of pre-RT, 2- and 4-week during-RT, and 
post-RT (generally first follow-up at 3 months after RT completion).
Measurements of Serum Tryptophan and Kynurenine
Serum tryptophan and kynurenine concentrations were measured using a high performance 
liquid chromatography system (Shimadzu LC20) as described before with minor 
modification (25,26). 25μl of serum samples were diluted with equal volumes of 30mM 
NaAc pH4.0 and deproteinated with perchloric acid. Kynurenine was detected on an UV 
channel at 360nm and tryptophan was detected on a fluorescence channel at 285nm 
excitation and 365nm emission. Samples were analyzed using Lab SolutionTM software 
(Shimadzu). Samples were quantified with external standards and at least one quality control 
samples were randomly inserted into every plate for reference. For quality control purposes, 
double-blinding duplicate/triplicate testing verified the assay reproducibility to be over 95%.
Statistical Analysis
OS and PFS were the primary endpoints. OS was computed from RT start to the date of 
death of any cause. PFS was defined from start of RT to the date of any progression or death. 
Patients were censored at last follow-up if progression or death had not occurred. Kaplan-
Meier log-rank test was applied to compare the survival difference between groups. Clinical 
variables with log-rank P<0.05 under univariate analysis were selected as co-variants for 
adjustment in multivariate analysis. Multivariate Cox proportional hazards model was used 
to estimate hazard ratios (HR) with 95% confidence interval (95% CI). The IDO-checkpoint 
associated molecules from the 4 time points were compared using repeated analysis of 
variance (ANOVA) (equivalent to paired t test for 2 groups). Considering 2 markers × 2 time 
points in survival analysis, Bonferroni correction for multiple testing was performed for 
statistical significance at a P<0.0125 (0.05/4) level. All statistical analyses were performed 
using IBM® SPSS Statistics 22.0 (IBM, Inc.). Scatter plot figures of IDO dynamic changes 
were generated using GraphPad Prism® (version 5.01).
Results
Study Population and Overall Clinical Outcomes
Of 182 patients enrolled, 110 patients staged III with quality samples available for IDO 
testing formed the primary study population. There were 103 Caucasian (94%) and 29 
(26%) females. The median age was 66 years. All patients (100%) received definitive dose 
Wang et al. Page 3
Cancer Res. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(≥ 60 Gy) of 3DCRT and 103 (94%) of whom underwent concurrent platinum-based 
chemotherapy. Table 1 details the patient demographic and clinical features. The median 
follow-up time was 56 months (95% CI, 49-63 months). The median OS and PFS were 23 
(95% CI, 17-29) and 11 (95% CI, 7-15) months, respectively. Univariate analysis showed 
that age (P=0.016), gender (P=0.040), tumor volume (P=0.010), KPS (P<0.001) and EQD2 
(P=0.014) were significant for OS. Younger, female, smaller tumor volume, higher KPS and 
higher EQD2 had better OS. However, only tumor volume (P=0.041), KPS (P=0.010) and 
EQD2 (P=0.004) were significant for PFS (Table 1). These clinical factors were thus 
selected as clinical co-variants for further multivariate analysis of IDO checkpoint associated 
parameters.
Dynamics of Kynurenine and K:T Ratio at Different Time Points
Serum kynurenine and K:T ratio changed heterogeneously through 4 time points from pre-
RT, to 2- and 4-week during-RT, and post-RT (Figure 1A-B). Mean kynurenine 
concentrations did not change significantly at 2-week of RT, but increased at 4-week during-
RT, and increased further post-RT. Kynurenine concentrations post-RT were significantly 
higher than that of other time points. The mean K:T ratio decreased from pre to 2-week and 
to 4-week during-RT, and increased sharply post-RT. The K:T ratio at the post-RT was 
significantly higher than that of pre- and during-RT time points. K:T ratio at 2-week was 
significantly lower than that of pre-RT under the paired t-test analysis (P=0.007).
Baseline IDO Biomarkers and Outcome
Kynurenine at pre-RT was not significantly correlated with OS (HR=1.03, 
95%CI=0.73-1.45; P=0.887) or PFS (HR=0.99, 95%CI=0.71-1.37; P=0.927) (Table 2). K:T 
ratio at pre-RT correlated significantly with OS (HR, 2.36; 95% CI, 1.21-4.59; P=0.011) and 
PFS (HR, 1.77; 95% CI, 1.02-3.05; P=0.042) (Figure 2A and 2B, Table 2) after adjusting for 
the clinical significant factors. However, only the P-value for OS remained significant after 
Bonferroni's correction. High K:T ratio correlated significantly with poorer survival.
Post-RT IDO Biomarkers and Outcome
None of the post-RT levels in kynurenine or K:T ratio was significant for OS or PFS. 
Among various RT-induced changes of these IDO checkpoint molecules, only change in 
kynurenine was significant. Using median as the cut-off, greater levels of post/pre 
kynurenine correlated significantly with worse OS (HR, 1.35, 95% CI, 1.09-1.68, P=0.006) 
and poorer PFS (HR, 1.31, 95% CI, 1.04-1.66, P=0.025). (Figure 3A and 3B, Table 2). 
However, only the P-value for OS remained significant after Bonferroni's correction.
Combined Effects of Baseline and Change of IDO Biomarker on OS, PFS and Metastasis
To study the combined effects of baseline and change of IDO activities, patients were 
stratified into the following 4 groups according to the medians of pre-RT K:T ratio and 
post/pre kynurenine: 1) low pre-RT K:T ratio and low post/pre kynurenine (favorable 
baseline and favorable change); 2) high pre-RT K:T ratio and low post/pre kynurenine 
(unfavorable baseline and favorable change); 3) low pre-RT K:T ratio and high post/pre 
kynurenine (favorable baseline and unfavorable change); 4) high pre-RT K:T ratio and high 
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post/pre kynurenine (unfavorable baseline and unfavorable change). There were significant 
differences in OS (P=0.002) (Figure 4A) and PFS (P=0.013) (Figure 4B) for these 4 groups. 
Patients in Group 1 achieved extremely long-term OS (the median OS has not been reached 
after up to 57 months of median follow-up), but a relatively low PFS of 14 (10-17) months. 
Patients in Group 2 had median OS and PFS of 25 (14-36) and 17 (0-45) months, 
respectively. The median OS and PFS (and their 95% CIs) were 36 (22-50) and 18 (0-45) 
months for Group 3, and 12 (8-17) and 6 (2-9) months for Group 4, respectively.
Pattern of failure analysis was performed for these 4 groups to study how baseline and 
change of the IDO differently impact on OS and PFS. Distant and local/regional failure were 
6/13 (46%) and 1/13 (8%), 0/15 (0%) and 7/15 (47%), 8/19 (42%) and 2/19 (11%), 4/10 
(40%) and 4/10 (40%) for Groups 1, 2, 3 and 4, respectively (P=0.019) (Figure 4C). 
Furthermore, those patients who developed distant progression in Group 1 had a median OS 
of 41 months, which was longer than that in group 3 and group 4 (23 and 9 months) 
(P=0.057) (Figure 4D).
Discussion
This study demonstrated that 1) RT caused significant reductions in IDO activity 
(represented by K:T ratio) during-RT but IDO increased significantly post-RT (after more 
radiation); 2) IDO at baseline and post-RT correlated significantly with OS and PFS; 3) RT-
induced change in kynurenine post-RT was significant for either OS or distant progression in 
an unusual manner (median OS did not reach, corresponded to 88 months mean OS with 
favorable baseline, and 0% distant progression under unfavorable baseline). These results 
support our hypotheses that RT can alter the IDO-mediated anti-tumor immune activity.
This study demonstrates that IDO activity at baseline is an important prognostic marker for 
patients with NSCLC treated with fractionated RT. This is in agreement with previous 
studies that baseline IDO immune status plays a prognostic role after surgery or 
chemotherapy (16,17,20-22). Our data demonstrated low activity of IDO, i.e. low level of 
kynurenine or low K:T ratio (favorable baseline), was significantly associated with better 
survival. The prognostic significance of baseline IDO biomarkers in our patients treated with 
RT may serve as a strong validation of above studies and clinically confirms the immune 
suppressive role of IDO in NSCLC (27). Although studies with larger sample sizes are 
needed for RT, this has clinical significance as knowing the prognosis of an individual 
patient may help triage the care plan of that patient.
More importantly, this study is the first to demonstrate that fractionated RT in NSCLC 
induces significant change of IDO-mediated immune activity level, and such change 
correlates with OS, PFS and unusual treatment outcomes in combination with baseline IDO 
activity. Studies in animal models have shown that hypo-fractionated RT can generate 
synergetic immune responses (3,5), and there are speculations and single-case reports about 
activation of anti-tumor immunity by hypo-fractionated RT (3,4). However, there are no 
reports in human studies showing that RT can generate anti-tumor immunity in a significant 
number of patients. Recent results in KYNOTE-001 phase 1 trial suggested that previous 
treatment with radiotherapy in patients with advanced NSCLC results in longer PFS and OS 
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with pembrolizumab treatment than that seen in patients who did not have previous 
radiotherapy (28). This findings supported that radiotherapy affects host immunity in 
NSCLC patients. Our study showed that patients with favorable RT-induced change in 
combination with favorable baselines (Group 1) corresponded to extremely long-term OS 
(>60% OS up to 57 months median follow-up), suggesting RT-induced immune activity 
change may generate memory T-cells for long-term tumor control. In addition, patients with 
favorable change and unfavorable baseline (Group 2) had 0% distant progression, suggesting 
that this RT-induced anti-tumor immunity may control occult tumor cells outside the RT 
fields, a phenomenon similar to abscopal effects. However, it is unclear why patients in 
Group 1 did not have similar “abscopal” effect as in Group 2. The underlying biologic 
mechanism for this phenomenon will require further research. We speculate that relatively 
small amount of anti-tumor immune cells were activated in Group 1 patients due to their 
favorable baseline status. They were not sufficient to control the occult diseases outside the 
RT fields in a short time, and local salvage treatment was required and able to control the 
distant metastasis developed from these occult diseases. Our data showed that the metastasis 
patients still had 41 months median OS, supporting our speculation.
Most interestingly, our data showed that RT can lead favorable or unfavorable changes of 
IDO immune activity varied with time point (dose level) or patient level. It is unclear what 
patient-specific factors influence these heterogeneous RT responses. We hypothesize that 
both underdose and overdose of RT will lead to unfavorable changes of immune activity. 
Underdose will not be sufficient to generate the favorable change, while overdose will 
damage the immune system and revert into the unfavorable status. Therefore, there is an 
optimal RT dose for maximal immune activation. Because patients and tumors have 
heterogeneous radiosensitivities, the optimal RT dose could be different for different 
patients. We found that median K:T ratio and median kynurenine concentration reduced in 
the initial phase of RT (at 2-week, lower doses). This statistically significant K:T ratio 
reduction suggests that IDO activity may be suppressed by anti-tumor immunity in some 
patients as early as 2-week after starting RT. Though median kynurenine levels tended to 
increase, median K:T ratio remained at low levels in the middle phase of RT (at 4-week), 
while both increased at later stages (post-RT status, high doses). Therefore, changes of these 
IDO-associated molecules during-RT may serve as potential biomarkers to determine the 
optimal individualized RT dose for each patient by determining when to stop excessive RT. 
However, a slight-increase of IDO or kynurenine concentration during RT may not be an 
indication of unfavorable change, because immune response to radiation damage of other 
normal tissues may also partially contribute to the increase. Further study is required to 
understand better the underlying mechanisms.
Additionally, the findings from this study may be relevant to blood biomarker to guide 
multimodality clinical trials. Anti-IDO agents are available commercially and clinical trials 
using various IDO inhibitors are in progress (29). Animal studies have revealed synergies 
between RT and anti-IDO agents (30). A pilot study using an IDO inhibitor after 
chemotherapy in stage III-IV NSCLC patients has generated promising results (31). A key 
question about combining RT with IDO inhibitor therapy and other immunotherapy drugs is 
the optimal RT dose and optimal time points to give IDO inhibitors. RT doses that activate 
anti-tumor immunity but do not cause excessive immune depletion are desirable.
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This study has limitations. One of them is serum sample availability. The numbers of 
available samples at different time points were diverse, which may impact study results, 
especially for inter-group comparisons. Also, the study was not powered for a subgroup 
analysis on chemotherapy-IDO activity association. Previous studies have shown synergy 
between chemotherapy and IDO inhibitors in promoting clinical responses. It is possible that 
potential synergistic effects of chemotherapy may have partially biased our results. Rather 
than a sole effect of RT, the observed phenomenon could be the combined effects of 
chemotherapy and radiotherapy.
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Figure 1. 
Dynamic changes of IDO-associated molecular activity during and post radiotherapy. The 
top panel shows individual and mean activity levels, and the bottom panel shows spaghetti 
plots for kynurenine (A) and K:T ratio (B) at four time points. P-values shown were from 
paired t-tests. Error bars at figures show 95% confidence interval (CI).
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Figure 2. 
Baseline IDO-mediated immune activity and treatment outcomes. Pre-RT K:T ratio for 
overall survival (A); Pre-RT K:T ratio for progression free survival (B).
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Figure 3. 
Changes of IDO-mediated immune activity and treatment outcomes. Changes of kynurenine 
after radiotherapy (Post/pre kynurenine) associated with overall survival (A) and progression 
free survival (B).
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Figure 4. 
Combined effects of baseline IDO biomarkers and post-RT change with survival and tumor 
progression. Patients were stratified into 4 groups according to the medians of pre-RT K:T 
ratio (baseline immune activity) and post/pre kynurenine (change of immune activity). 
Group 1: favorable baseline and favorable change; Group 2: unfavorable baseline and 
favorable change; Group 3: favorable baseline and unfavorable change; Group 4: 
unfavorable baseline and change. (A) Comparison of overall survival (OS) in 4 groups, 
Group 1 showing extremely long-term OS. (B) Comparison of progression free survival 
(PFS) in 4 groups.
(C) Comparison of tumor local/regional and distant progressions in 4 groups. The favorable 
baseline (Groups 1 and 3) corresponded to less local/regional progression, while Group 2 
had 0% distant progression.
(D) Comparison of OS for patients developed distant metastasis for Groups 1, 3 and 4.
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